MAPT and Alzheimer disease: Thirty‐three different p‐tau assays measured paired plasma and cerebrospinal fluid (CSF) from 40 participants (25 with “AD pathology” and 15 with “non‐AD pathology” by CSF amyloid beta [Aβ]42/Aβ40 and p‐tau181 criteria).